Xlife Sciences AG / CH0461929603
20.12.2023 - 07:00:20Xlife Sciences AG paves the way for the next successful out-licensing and announces cooperation with Quant Biomarkers AG for the development of advanced biomarkers for kidney diseases
| Xlife Sciences AG / Key word(s): Letter of Intent/Partnership 20.12.2023 / 07:00 CET/CEST Xlife Sciences AG (SIX: XLS) and Quant Biomarkers AG are pleased to announce an exclusive collaboration for the licensing of innovative biomarkers aimed at the early detection of chronic kidney diseases (CKD). Current medical standards allow the detection of kidney disease when nearly 50% of the kidney function is already lost. Subsequent therapy slows the progression towards dialysis or kidney replacement, but does not lead to a curation of the disease. Addressing this issue, the global renal biomarkers market, valued at US$ 1.13 billion in 2021, is projected to reach US$ 1.88 billion by 2027, growing at a CAGR of 8.70%. Xlife Sciences AG, through its portfolio company x-kidney diagnostics GmbH, has identified biomarkers that predict kidney failure at its pre-clinical stages. Concurrently, Quant Biomarkers AG is actively pursuing intellectual property rights for specific combinations of kidney biomarkers, intending to use them for both diagnostic and prognostic purposes. This exclusive collaboration lays the foundation for both entities to enter licensing negotiations, in which Quant Biomarkers AG receives a license to further validate and develop the identified biomarkers. This partnership aims to change how we treat early chronic kidney disease (CKD). We utilize biobanks to predict disease progress early, making precise decisions before any kidney damage, and allowing for preemptive therapy. Both parties will negotiate and agree on milestone payments and royalty payments as full consideration for the Licensed IP. Oliver R. Baumann, CEO of Xlife Sciences AG, stated «Our collaboration with Quant Biomarkers AG represents a pivotal moment in our mission to transform healthcare through innovation. This partnership harnesses our combined expertise to address the urgent need for early detection of chronic kidney diseases, setting a new standard in diagnostic precision and patient care. » Dr. Sanja Baumann-Tomovska, CEO of Quant Biomarkers AG, elaborated «We are excited to team up with Xlife Sciences AG and look forward to forming innovative partnerships that will pave the way for a groundbreaking diagnostic solution, securing kidney health for 800 million patients worldwide. » This collaboration marks a significant step forward in addressing a critical healthcare challenge and reflects both Quant Biomarkers AG's and Xlife Sciences AG's commitment to innovation and excellence in the life sciences sector. Financial calendar
Contakt Information for investors and journalists: Xlife Sciences AG, Dr. Dennis Fink, dennis.fink@xlifesciences.ch Information related to Quant Biomarkers AG: Dr. Sanja Baumann Tomovska, sanja@quant-biomarkers.swiss Xlife Sciences AG, Talacker 35, 8001 Zurich, Switzerland, Phone +41 44 385 84 60 info@xlifesciences.ch, www.xlifesciences.ch Commercial Register Zurich CHE-330.279.788 Stock Exchange: SIX Swiss Exchange About Xlife Sciences AG (SIX: XLS) Xlife Sciences is a Swiss company focused as incubator and accelerator on the value development and commercialization of promising research projects from universities and other research institutions in the life sciences sector, with the aim of providing solutions for high unmet medical needs and a better quality of life. The goal is to bridge research and development to healthcare markets. Xlife Sciences takes carefully selected projects in the four areas of technological platforms, biotechnology/ therapies, medical technology, and artificial intelligence/digital health to the next stage of development, and participates in their subsequent performance. For more information, visit www.xlifesciences.ch About Quant Biomarkers AG Quant Biomarkers AG is dedicated to enhancing biomarker technology to identify and foresee the initial indications of chronic diseases, enabling tailored interventions in the field of longevity medicine. Their approach is grounded in targeting the underlying biology of aging, which forms the basis of our disease prevention strategies and the creation of regenerative treatments. By merging medical science with digital technology, Quant Biomarkers AG facilitates early access to optimized and effective healthcare choices, aiming to improve health outcomes and lower healthcare expenses. Quant Biomarkers pursue active research collaboration and EHR data analysis with Clinical Research Department, Hvidovre University Hospital, Copenhagen, Denmark and DTU with University Hospital Basel (USB), Switzerland. For more information, visit www.quant-biomarkers.swiss/ Disclaimer Some of the information contained in this media release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Xlife Sciences undertakes no obligation to publicly update or revise any forward-looking statements. End of Media Release |
| Language: | English |
| Company: | Xlife Sciences AG |
| Talacker 35 | |
| 8001 Zürich | |
| Switzerland | |
| Phone: | +41 44 385 84 60 |
| E-mail: | info@xlifesciences.ch |
| Internet: | www.xlifesciences.ch |
| ISIN: | CH0461929603 |
| Valor: | A2PK6Z |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 1800611 |
| End of News | EQS News Service |
| |
